The University of Southampton
University of Southampton Institutional Repository

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial

Dahlén, Sven-Erik, Malmstrom, Kerstin, Nizankowska, Ewa, Dahlén, Barbro, Kuna, Piotr, Kowalski, Marek, Lumry, William R., Picado, César, Stevenson, Donald D., Bousquet, Jean, Pauwels, Romain, Holgate, Stephen T., Shahane, Aditi, Zhang, Ji, Reiss, Theodore F. and Szczeklik, Andrew (2002) Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial American Journal of Respiratory and Critical Care Medicine, 165, (1), pp. 9-14.

Record type: Article

Abstract

Leukotriene antagonists block the proinflammatory actions of leukotrienes (LT) and have been introduced as new treatments for asthma. Conventional therapy with glucocorticosteroids does not inhibit the biosynthesis of leukotrienes. We therefore tested whether addition of the leukotriene receptor antagonist montelukast was of therapeutic benefit in a group of aspirin-intolerant patients with asthma of whom 90% already were treated with moderate to high doses of glucocorticosteroids. Under double-blind conditions, 80 aspirin-intolerant patients with asthma were randomized to receive 4 wk oral treatment of either 10 mg of montelukast or placebo once daily at bedtime. Pulmonary function was measured as forced expiratory volume in 1 s (FEV1) once a week in the clinic and daily as morning and evening peak expiratory flow rate (PEFR). Asthma symptoms and use of rescue bronchodilator were also recorded daily.
Asthma specific quality of life (QoL) was assessed before and after the treatments. The group receiving montelukast showed a remarkable improvement of their asthma, whereas the group given placebo showed no change. Thus, from equal baseline values, the mean difference between the groups over the 4-wk treatment period was 10.2% for FEV1 and 28.0 L for morning PEFR (p for both < 0.001). The improved pulmonary function in the group receiving montelukast occurred at the same time as 27% less bronchodilator was used (p < 0.05), and it was associated with fewer asthma symptoms than in the group given placebo, including 1.3 nights more of sleep per week and 54% fewer asthma exacerbations (p < 0.05). There was also an improvement in asthma-specific QoL (p < 0.05). The therapeutic response to montelukast was consistent across patients with different baseline characteristics and did not correlate with baseline urinary LTE4. Addition of a leukotriene receptor antagonist such as montelukast improves asthma in aspirin-intolerant patients over and above what can be achieved by glucocorticosteroids.

Full text not available from this repository.

More information

Published date: 2002
Keywords: asthma therapy, leukotriene modifiers, glucocorticosteroids, airway inflammation

Identifiers

Local EPrints ID: 27011
URI: http://eprints.soton.ac.uk/id/eprint/27011
ISSN: 1073-449X
PURE UUID: 1962fefb-b0cc-483c-b828-dcee862bb267

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 17 Jul 2017 16:05

Export record

Contributors

Author: Sven-Erik Dahlén
Author: Kerstin Malmstrom
Author: Ewa Nizankowska
Author: Barbro Dahlén
Author: Piotr Kuna
Author: Marek Kowalski
Author: William R. Lumry
Author: César Picado
Author: Donald D. Stevenson
Author: Jean Bousquet
Author: Romain Pauwels
Author: Aditi Shahane
Author: Ji Zhang
Author: Theodore F. Reiss
Author: Andrew Szczeklik

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×